。Technicals: QTRX dropped to October-November low at 19 from July's 36 high and then consolidated between 19 and 22.5 for a month before breaking out today on above average volume. This actions signify a bottom is in place for the the stock. Its trend is up since it has broken above its 20 and 50 day moving averages. Its next resistance is 200 day moving average at 25.22 then 28. Support is between 22 and 22.5.
。Good revenue growth: Q3 Revenue: $14.9M (+41%); product sales: $10.7M (+80%) driven by the launch of its HD-X Analyzer and accelerated adoption of its Simoa technology.
。On November 4， QTRX announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix' proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will allow Siemens Healthineers to begin developing blood-based Nf-L The administration marks yet another significant milestone in Quanterix' mission to provide early detection of disease, measurements for treatment efficacy, and disease progression for neurological disorders. The UmanDiagnostics acquisition allows Quanterix to supply researchers globally with the "best- In-class" Simoa Nf-L assays, while continuing to innovate new digital biomarkers to advance the field of research in diagnostics for neurological disorders.
。Financials：Debt/Equity is only 0.10. Current Ratio is a healthy 5.4.
。Only 22.61 million shares float and can easily pushed up.
。Increasing institution interest, institutions own 72% of QTRX stock.
。Canaccord Genuity re-affirmed Buy rating, target 35. Two analyst rated QTRX Strong Buy and two rated Buy. Analysts consensus target is 34.
生命科学公司Quanterix Corporation（QTRX）在北美，欧洲，中东，非洲和亚太地区开发和销售超灵敏的数字免疫测定平台，该平台可促进生命科学研究和诊断的精确。该公司提供Simoa HD-1仪器，这是一种灵敏的自动多重蛋白检测平台。 SR-X仪器使研究人员能够将Simoa检测技术应用于各种应用，包括直接检测核酸。它还开发了基于Simoa平面阵列技术的SP-X仪器，用于测量多重化学发光免疫测定。
。技术上QTRX从7月份的36高点跌至10-11月份的19低价，然后在19点至22.5点之间盘整了一个月，于今天线上突破交易区间。这些都股票已经触底的显示。由于它已经突破了20天和50天移动平均线，因此其趋势为上升。它的下一个阻力是200日移动平均线水平25.22，然后是28。支撑位在22和22.5之间。
。良好的收入增长：第三季度收入：1,490万美元（+ 41％）；产品销售：推出HD-X分析仪并加速采用Simoa技术推动了1,070万美元的销售（增长80％）。
。11月4日QTRX宣布已与Siemens Healthineers达成许可和供应安排，以采用Quanterix专有的Nf-L抗体，该抗体最近从UmanDiagnostics手中收购。获得Nf-L抗体将使Siemens Healthineers可以开始开发基于血液的Nf-L。这标志着Quanterix使命的另一个重要里程碑，该使命旨在提供疾病的早期发现，治疗效果的测量以及神经系统疾病的疾病进展。通过收购UmanDiagnostics，Quanterix可以为全球研究人员提供“同类最佳”的Simoa Nf-L分析法，同时继续创新新的数字生物标记物，以推进神经系统疾病诊断研究领域。
。财务：债务/股本仅为0.10。流动比率为5.4。
。只有2261万股流通，股价可以轻易被推高。
。机构的参与增加，机构现拥有QTRX股份的72％。
。Canaccord Genuity重申买入评级，目标价为35。两位分析师对QTRX 的评级为强买，另外两位评级为买入。分析师们的共识目标是34。
No comments:
Post a Comment